| Carol Mcshane, RN, MSN | |
|
457 Calavant Hill Rd, Charlestown, NH 03603 | |
| (603) 505-8120 | |
| Not Available |
| Full Name | Carol Mcshane |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse - Case Management |
| Location | 457 Calavant Hill Rd, Charlestown, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124741152 | NPI | - | NPPES |
| 055672-21 | Other | NH | NH RN LICENSE |
| Mailing Address | Practice Location Address |
|---|---|
| Carol Mcshane, RN, MSN 457 Calavant Hill Rd, Charlestown, NH 03603 Ph: (603) 505-8120 | Carol Mcshane, RN, MSN 457 Calavant Hill Rd, Charlestown, NH 03603 Ph: (603) 505-8120 |
News Archive
Breast cancer is the most frequent type of cancer in women and currently accounts for 29% of all new cancer cases in the U.S. Wide-ranging mammography screening programs have been set up for early diagnosis. However, even if two physicians assess the x-rays, which is the usual procedure in Europe, this often leads to wrong decisions: about 20% of patients with cancer are diagnosed as being cancer-free, whereas about 20% of cancer-free patients are diagnosed with cancer.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it received FDA Fast Track designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients suffer from the progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
The lack of a gene called LBP-1a in the mouse embryo prevents normal growth of blood vessels in the placenta. This finding suggests that a similar defect in humans could play a role in fetal growth retardation, infant mortality and spontaneous abortion.
Removing new neurons born after a brain injury reduces seizures in mice, according to new research in JNeurosci. This approach could potentially help prevent post-injury epilepsy.
Access Scientific, Inc. today announced it has received FDA 510(k) clearance for the POWERWAND — an extended-dwell, power-injectable 3.1 inch IV catheter delivered by means of The WAND's proprietary Accelerated Seldinger Technique.
› Verified 7 days ago
Mrs. Sharon Patricia Gamache, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 164 Old Springfield Rd, Charlestown, NH 03603 Phone: 603-826-0840 Fax: 603-826-0839 | |
Misha Boris Yakovleff, REGISTERED NURSE Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 28 Elm St, Charlestown, NH 03603 Phone: 603-826-3704 | |
Mrs. Tamara Lee Golden, HNB-BC, WHE, NBC-HWC Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 276 Main St, Charlestown, NH 03603 Phone: 603-826-4955 |